参考文献/References:
[1] SEIB C D, SOSA J A. Evolving understanding of the epidemiology of thyroid cancer[J]. Endocrinology and Metabolism Clinics of North America, 2019, 48(1): 23-35.
[2] 王永斌, 邓智勇, 肖世闻, 等. 分化型甲状腺癌术后抑制状态下血清甲状腺球蛋白水平检测的临床诊断价值[J]. 现代检验医学杂志, 2019, 34(5): 133-134, 138. WANG Yongbin, DENG Zhiyong, XIAO Shiwen, et al. Clinical value of serumnon-stimulated thyroglobulin(nstg) in differentiated thyroid cancer (DTC) patients in after thyroidectomy[J]. Journal of Modern Laboratory Medicine, 2019, 34(5): 133-134, 138.
[3] MAIUTHED A, PRAKHONGCHEEP O ,CHANVORACHOTE P. Microarray-based analysis of genes, transcription factors, and epigenetic modifications in lung cancer exposed to nitric oxide[J].Cancer Genomics & Proteomics, 2020, 17(4): 401-415.
[4] HE Jie, HUANG Hongli, DU Yanlei, et al. Association of DCBLD2 upregulation with tumor progression and poor survival in colorectal cancer[J]. Cellular Oncology (Dordrecht), 2020, 43(3): 409-420.
[5] CHUANG H C, CHANG C C, TENG C F, et al. MAP4K3/GLK promotes lung cancer metastasis by phosphorylating and activating IQGAP1[J]. Cancer Research, 2019, 79(19): 4978-4993.
[6] CHUANG H C, TAN T H. MAP4K3/GLK in autoimmune disease, cancer and aging[J]. Journal of Biomedical Science, 2019, 26(1): 82.
[7] 张新洲, 刘劲松, 许娴, 等. 2005~2016 年中国甲状腺癌发病和死亡趋势分析[J]. 中华肿瘤防治杂志,2022, 29(24): 1725-1733. ZHANG Xinzhou, LIU Jinsong, XU Xian, et al. Trends of thyroid cancer incidence and mortality in China from 2005 to 2016[J]. Chinese Journal of Cancer Prevention and Treatment, 2022, 29(24): 1725-1733.
[8] 徐志勇, 马晓良. 甲状腺癌患者术后复发风险预测的列线图模型建立[J]. 实用肿瘤学杂志, 2021,35(1): 35-40. XU Zhiyong, MA Xiaoliang. Establishment of a nomogram model for predicting the risk of postoperative recurrence in patients with thyroid cancer[J]. Practical Oncology Journal,2021, 35(1): 35-40.
[9] DONG Yang, MA Weiming, SHI Zhenduo, et al. Role of NRP1 in bladder cancer pathogenesis and progression[J]. Frontiers in Oncology, 2021, 11: 685980.
[10] XIE Pan, LIU Junyan, YAN Han, et al. Pancancer analyses identify DCBLD2 as an oncogenic,immunological, and prognostic biomarker[J]. Frontiers in Pharmacology, 2022, 13: 950831.
[11] FENG Zengyu, LI Kexian, WU Yulian, et al. Transcriptomic profiling identifies DCBLD2 as a diagnostic and prognostic biomarker in pancreatic ductal adenocarcinoma[J]. Frontiers in Molecular Biosciences, 2021, 8: 659168.
[12] TAN Jiuting, LI Chunpu, REN Lijue, et al. MiR-451a suppresses papillary thyroid cancer cell proliferation and invasion and facilitates apoptosis through targeting DCBLD2 and AKT1[J]. Molecular and Cellular Probes,2022, 66: 101863.
[13] CHEN Xiaosu, L? Yajing, XU Kejia, et al. DCBLD2 mediates epithelial-mesenchymal transition-induced metastasis by cisplatin in lung adenocarcinoma[J].Cancers, 2021, 13(6): 1403.
[14] CHEN Hualin, YANG Wenjie, LI Yingjie, et al. Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients[J]. Frontiers in Immunology, 2023, 14:1198878.
[15] HSU C L, LEE E X, GORDON K L, et al. MAP4K3 mediates amino acid-dependent regulation of autophagy via phosphorylation of TFEB[J]. Nature Communications, 2018, 9(1): 942.
[16] CHUANG H C, HSUEH C H, HSU P M, et al. SARSCoV-2 spike protein enhances MAP4K3/GLK-induced ACE2 stability in COVID-19[J]. EMBO Molecular Medicine, 2022, 14(9): 15904-15914.
[17] WANG Ziquan, HAN Zhengxiang, ZHANG Lansheng,et al. MicroRNA-98-5p regulates the proliferation and apoptosis of A549 cells by targeting MAP4K3[J].Oncology Letters, 2019, 18(4): 4288-4293.
[18] ZHUANG Qingyang, HUANG Zhangzhou, ZHUANG Wu, et al. Knockdown of circ-RAD23B inhibits nonsmall cell lung cancer progression via the miR-142-3p/MAP4K3 axis[J]. Thoracic Cancer, 2022, 13(5): 750-760.
[19] BRANCH M R, HSU C L, OHNISHI K,et al. MAP4K3 inhibits sirtuin-1 to repress the LKB1-AMPK pathway to promote amino acid-dependent activation of the mTORC1 complex[J]. Life Science Alliance, 2023,6(8): e202201525.
[20] LIU Fangzhou, YIN Rong, CHEN Xinyuan, et al. Over-expression of miR-206 decreases the euthyroxresistance by targeting MAP4K3 in papillary thyroid carcinoma[J]. Biomedecine & Pharmacotherapie, 2019,114: 108605.
相似文献/References:
[1]彭继英a,杨红杰b,石晓欣a,等.细针穿刺细胞学检查在甲状腺癌碘-131 治疗后复发诊断中的应用价值[J].现代检验医学杂志,2020,35(01):127.[doi:10.3969/j.issn.1671-7414.2020.01.033]
PENG Ji-yinga,YANG Hong-jieb,SHI Xiao-xina,et al.Application Value of Fine Needle Aspiration Cytology in Recurrence
Diagnosis of Thyroid Cancer after Iodine-131 Treatment[J].Journal of Modern Laboratory Medicine,2020,35(02):127.[doi:10.3969/j.issn.1671-7414.2020.01.033]
[2]赵芳芳,郭 红,陈 嘉.LncRNA TUG1 在甲状腺癌组织中的表达及其对细胞增殖和迁移的影响[J].现代检验医学杂志,2020,35(06):42.[doi:doi:10.3969/j.issn.1671-7414.2020.06.011]
ZHAO Fang-fang,GUO Hong,CHEN Jia.Expression of LncRNA TUG1 in Thyroid Carcinoma Tissues and Its Effect onCell Proliferation and Migration[J].Journal of Modern Laboratory Medicine,2020,35(02):42.[doi:doi:10.3969/j.issn.1671-7414.2020.06.011]
[3]仲亚东,孔德桐,马伯敏.甲状腺癌患者组织及手术前后血清中NR3C2 和ZEB1 表达水平及其与预后价值研究[J].现代检验医学杂志,2023,38(04):94.[doi:10.3969/j.issn.1671-7414.2023.04.017]
ZHONG Yadong,KONG Detong,MA Bomin.Study on the Expression Level of NR3C2 and ZEB1 in Thyroid Cancer Tissue and Serum of Patients before and after Surgery and Their Prognostic Value[J].Journal of Modern Laboratory Medicine,2023,38(02):94.[doi:10.3969/j.issn.1671-7414.2023.04.017]
[4]张廷华a,胡友元b,袁 博.miR-100-5p 对甲状腺癌细胞增殖与凋亡调控作用的实验研究[J].现代检验医学杂志,2024,39(04):56.[doi:10.3969/j.issn.1671-7414.2024.04.011]
ZHANG Tinghuaa,HU Youyuanb,YUAN Bo.Experimental Study on the Regulatory Effects of miR-100-5p on Proliferation and Apoptosis of Thyroid Cancer Cells[J].Journal of Modern Laboratory Medicine,2024,39(02):56.[doi:10.3969/j.issn.1671-7414.2024.04.011]